Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Finished Goods (2018 - 2025)

Jaguar Health (JAGX) has disclosed Finished Goods for 8 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Finished Goods rose 60.78% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 60.78% increase, with the full-year FY2024 number at $1.1 million, up 76.91% from a year prior.
  • Finished Goods was $1.2 million for Q3 2025 at Jaguar Health, up from $1.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $1.7 million in Q2 2022 to a low of $553000.0 in Q1 2021.
  • A 5-year average of $1.0 million and a median of $949000.0 in 2025 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: surged 105.06% in 2021, then tumbled 53.55% in 2023.
  • Jaguar Health's Finished Goods stood at $892000.0 in 2021, then skyrocketed by 48.43% to $1.3 million in 2022, then crashed by 53.55% to $615000.0 in 2023, then skyrocketed by 76.91% to $1.1 million in 2024, then increased by 13.05% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Finished Goods are $1.2 million (Q3 2025), $1.2 million (Q2 2025), and $949000.0 (Q1 2025).